NIFTY 50

20-25% topline growth, 200-250 bps improvement in margins expected, says Sequent Scientific

Updated : April 30, 2018 03:35:32 IST

Sequent Scientific is in focus as the company recently demerged its human active pharmaceutical ingredients (API) business into separate company, Solara Active Pharma.

Manish Gupta, CEO of Sequent Scientific said that the relisting process was on and expected the listing to occur by the end of May.

“Last quarter we had declared our continuing operations results and on that basis, we were clocking a quarterly revenue of about Rs 225 crore which is annualized to Rs 900 crore,” he said.

Talking about margin, he said, “we are very bullish on animal health business... we are targeting between 20-25 percent topline growth and 200-250 bps improvement in our EBTIDA margin year-on-year in the medium-term.”
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you